Glycogen content in the gastric mucosa of partially resected stomach; a possible relationship with the development of cancer

Skwarski, L; Namiot, Z; Stasiewicz, J; Kemonä, A; Kralisz, Maciej; Górski, Jan

doi:10.1016/s0304-3835(98)00016-0

Cited by 6 publications

(5 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…More importantly, previous study suggested that glycogen metabolism may play a central role in cancer progression. It was demonstrated that compared with normal tissues, solid tumor had a higher glycogen content and the correct storage and management of glycogen may be relevant to cancer cell survival [46–49], implying the possible modulatory effect of PYGM in cancer. Also, another study speculated that PYGM may be implicated in gastric cancer via the insulin resistance pathway [50].…”

Section: Discussionmentioning

confidence: 99%

Bioinformatics-based discovery of PYGM and TNNC2 as potential biomarkers of head and neck squamous cell carcinoma

Jin¹,

Yang²

2019

Bioscience Reports

View full text Add to dashboard Cite

Head and neck squamous cell carcinoma (HNSCC) is an aggressive malignancy with high morbidity and mortality rates and ranks as the sixth most common cancer all over the world. Despite numerous advancements in therapeutic methods, the prognosis of HNSCC patients still remains poor. Therefore, there is an urgent need to have a better understanding of the molecular mechanisms underlying HNSCC progression and to identify essential genes that could serve as effective biomarkers and potential treatment targets. In the present study, original data of three independent datasets were downloaded from the Gene Expression Omnibus database (GEO) and R language was applied to screen out the differentially expressed genes (DEGs). PYGM and TNNC2 were finally selected from the overlapping DEGs of three datasets for further analyses. Transcriptional and survival data related to PYGM and TNNC2 was detected through multiple online databases such as Oncomine, Gene Expression Profiling Interactive Analysis (GEPIA), cBioportal, and UALCAN. Quantitative real-time polymerase chain reaction (qPCR) analysis was adopted for the validation of PYGM and TNNC2 mRNA level in HNSCC tissues and cell lines. Survival curves were plotted to evaluate the association of these two genes with HNSCC prognosis. It was demonstrated that PYGM and TNNC2 were significantly down-regulated in HNSCC and the aberrant expression of PYGM and TNNC2 were correlated with HNSCC prognosis, implying the potential of exploiting them as therapeutic targets for HNSCC treatment or potential biomarkers for diagnosis and prognosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Bioinformatics-based discovery of PYGM and TNNC2 as potential biomarkers of head and neck squamous cell carcinoma

Jin¹,

Yang²

2019

Bioscience Reports

View full text Add to dashboard Cite

show abstract

“…It may be noted in support that the glycogen level in cancer is independent of the host's nutritional state. 7 Skwarski et al 28 reported that the risk of gastric cancer recurrence, which increases with the time from surgery, may be related to glycogen storage. Thus, it may be possible that an artificial decrease in the amount of glycogen is capable of inhibiting cancer growth by keeping the cell cycle in the state of G 1 stop or G 0 .…”

Section: Discussionmentioning

confidence: 99%

Estimation of glycogen levels in human colorectal cancer tissue: relationship with cell cycle and tumor outgrowth

Takahashi

Satomi

Yano

et al. 1999

Journal of Gastroenterology

View full text Add to dashboard Cite

In this study, we quantitatively measured glycogen levels in tissue samples obtained from tumors, regions adjacent to tumor, and regions of normal colorectum to determine whether the levels were related to cell cycle and cancer growth. Glycogen levels were analyzed in relation to histopathological factors, (tumor size and stage of disease) and cell cycle progression. The glycogen level was found to be highest in the cancer tissue, lower in normal tissue, and lowest in the adjacent tissue. The difference in glycogen level between the cancer tissue and the other two regions was significant (P < 0.05). There was a negative correlation between glycogen level and tumor size, but it was not significant. The level of glycogen in cancer tissues decreased as the stage of the disease progressed, but a significant difference was not found between stages. There was a negative correlation between the glycogen level and the proliferation index. There was a positive correlation between the glycogen level and the proportion of cancer cells in G1 phase, while there was a negative correlation with S and G2M phases. Glycogen levels were highest in cancers with a high proportion of cells in G1, and decreased with progression to S phase. It may be that glycogen is utilized in the progression to S phase, and the cancer tissues are supplied with glycogen from the tumors themselves as well as their adjacent tissues. Cancer growth may be inhibited by artificial control of the glycogen level in the G1 phase of cancer cells.

show abstract

“…For example, a high concentration of glycogen can activate AMP-activated protein kinase (AMPK), and the continuous activation of AMPK may cause cell aging and inhibit multiplication. Skwarski et al 40 reported that the risk of STAD recurrence increased with prolonged operation time, which may be associated with glycogen storage during surgery. We note that it is possible to artificially reduce the amount of glycogen, thereby inhibiting the growth of cancer by maintaining the cell cycle at the G1 stop or G0 states.…”

Section: Discussionmentioning

confidence: 99%

Protein Phosphatase 1 Regulatory Subunit 3: A Prognostic Biomarker in Stomach Adenocarcinoma

Zhu¹,

Liao²,

Wu³

et al. 2022

IJGM

View full text Add to dashboard Cite

Purpose This study aimed to determine the potential application of the protein phosphatase 1 regulatory subunit 3 ( PPP1R3B ) gene as a prognostic marker in stomach adenocarcinoma (STAD), as well as its potential mediating biological processes and pathways. Materials and Methods Differential expression analyses were performed using the TIMER2.0 and UALCAN databases. Complete RNA-seq data and other relevant clinical and survival data were acquired from The Cancer Genome Atlas (TCGA). Univariate survival analyses, Cox regression modelling, and Kaplan–Meier curves were implemented to investigate the associations between PPP1R3B gene expression and clinical pathologic features. A genome wide gene set enrichment analysis (GSEA) was conducted to define the underlying molecular mechanisms mediating the observed associations between the PPP1R3B gene and STAD development. Results We found that PPP1R3B was overexpressed in STAD tissues, and that higher PPP1R3B expression correlated with worse prognoses in patients with STAD. Comprehensive survival analyses suggested that PPP1R3B might be an independent predictive factor for survival time in patients with STAD. The prognostic relationship between PPP1R3B and STAD was also verified using Kaplan–Meier curves. Patients with higher PPP1R3B levels had a shorter clinical survival time on average. Additionally, a GSEA demonstrated that PPP1R3B might be involved in multiple biological processes and pathways. Conclusion Our findings demonstrate that the PPP1R3B gene has utility as a potential molecular marker for STAD prognoses.

show abstract

Glycogen content in the gastric mucosa of partially resected stomach; a possible relationship with the development of cancer

Cited by 6 publications

References 14 publications

Bioinformatics-based discovery of PYGM and TNNC2 as potential biomarkers of head and neck squamous cell carcinoma

Bioinformatics-based discovery of PYGM and TNNC2 as potential biomarkers of head and neck squamous cell carcinoma

Estimation of glycogen levels in human colorectal cancer tissue: relationship with cell cycle and tumor outgrowth

Protein Phosphatase 1 Regulatory Subunit 3: A Prognostic Biomarker in Stomach Adenocarcinoma

Contact Info

Product

Resources

About